Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
EA2201
Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer
- NCT04751370 ↗
- Active, not recruiting
- National Cancer Institute (NCI)
- Standard
We haven't built an HCP commentary report on EA2201 (nivolumab plus ipilimumab in MSI-H/dMMR locally advanced rectal adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EA2201 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 14 |
The trial
ClinicalTrials.gov- Official title
- A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Locally Advanced Rectal Adenocarcinoma; Stage II Rectal Cancer AJCC v8; Stage III Rectal Cancer AJCC v8
- Interventions
- Computed Tomography; Ipilimumab; Magnetic Resonance Imaging; Nivolumab; Radiation Therapy; Sigmoidoscopy; Total Mesorectal Excision
- Arms
- Treatment (nivolumab, ipilimumab, radiation therapy, TME) · Experimental
- Enrollment
- 31 (estimated)
- Primary outcomes
- Pathological complete response
- Sponsor
- National Cancer Institute (NCI)
- Start
- Feb 8, 2022
- Primary completion
- Jun 30, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04751370 · updated Oct 22, 2026